Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein. by Rosowski, Emily E et al.
UC Merced
UC Merced Previously Published Works
Title
Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii 
dense granule protein.
Permalink
https://escholarship.org/uc/item/56v2s71f
Journal
The Journal of experimental medicine, 208(1)
ISSN
0022-1007
Authors
Rosowski, Emily E
Lu, Diana
Julien, Lindsay
et al.
Publication Date
2011-01-03
DOI
10.1084/jem.20100717
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Article
The Rockefeller University Press $30.00
J. Exp. Med. Vol. 208 No. 1 195-212
www.jem.org/cgi/doi/10.1084/jem.20100717
195
Toxoplasma gondii is an obligate intracellular para-
site capable of infecting a wide range of warm-
blooded hosts, including humans. T. gondii 
establishes a lifelong chronic infection in the 
host by evading and subverting the immune sys-
tem. T. gondii infection is usually asymptomatic 
in healthy humans but can lead to flu-like and 
neurological symptoms in immunosuppressed 
patients and the fetuses of pregnant women 
infected for the first time. The vast majority of 
T. gondii strains isolated from Europe and North 
America belong to three clonal lineages, types I, 
II, and III, which differ in many phenotypes, in-
cluding virulence (Saeij et al., 2005). In mice, 
type I strains are categorically lethal, with an 
LD100 = 1, whereas type II or type III infec-
tions are not (LD50 ≈ 102 and ≈ 105, respectively; 
Sibley and Boothroyd, 1992; Saeij et al., 2006). 
Strain differences in the modulation of host im-
mune signaling pathways are one way by which 
this diversity arises. For example, the strain- 
specific modulation of the STAT3/6 signaling 
pathway by the secreted kinase ROP16 accounts 
for some of the strain differences in virulence 
(Saeij et al., 2006). Evidence also exists for the 
strain-specific modulation of NF-B (Robben 
et al., 2004), an important host signaling path-
way in the regulation of inflammatory, immune, 
and antiapoptotic responses.
The NF-B family of transcription factors 
is composed of five members: p50 (NF-B1), 
p52 (NF-B2), p65 (RelA), RelB, and c-Rel 
(Vallabhapurapu and Karin, 2009). In unstimu-
lated cells, homo- or heterodimers of NF-B 
are sequestered in the cytoplasm by members 
of the IB (inhibitor of B) family. Activation 
of NF-B is initiated by the degradation of IB 
proteins. This occurs via the activation of kinases 
called IB kinases (IKKs), which phosphorylate 
two serine residues located in IB regulatory 
domains, leading to their ubiquitination and 
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Strain-specific activation of the NF-B 
pathway by GRA15, a novel Toxoplasma 
gondii dense granule protein
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NF-B is an integral component of the immune response to Toxoplasma gondii. Although 
evidence exists that T. gondii can directly modulate the NF-B pathway, the parasite-
derived effectors involved are unknown. We determined that type II strains of T. gondii 
activate more NF-B than type I or type III strains, and using forward genetics we found 
that this difference is a result of the polymorphic protein GRA15, a novel dense granule 
protein which T. gondii secretes into the host cell upon invasion. A GRA15-deficient type II 
strain has a severe defect in both NF-B nuclear translocation and NF-B–mediated 
transcription. Furthermore, human cells expressing type II GRA15 also activate NF-B, 
demonstrating that GRA15 alone is sufficient for NF-B activation. Along with the rhoptry 
protein ROP16, GRA15 is responsible for a large part of the strain differences in the induc-
tion of IL-12 secretion by infected mouse macrophages. In vivo bioluminescent imaging 
showed that a GRA15-deficient type II strain grows faster compared with wild-type, most 
likely through its reduced induction of IFN-. These results show for the first time that a 
dense granule protein can modulate host signaling pathways, and dense granule proteins 
can therefore join rhoptry proteins in T. gondii’s host cell–modifying arsenal.
© 2011 Rosowski et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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used a type I strain of T. gondii, suggesting that different obser-
vations might be the result of different cell types and/or host 
species. Strain differences have been observed in the manipu-
lation of the host NF-B pathway by T. gondii. Type II strains 
were shown to cause the translocation of NF-B to the nu-
cleus of mouse splenocytes and mouse BM-derived macro-
phages (BMMs), whereas type I strains did not (Dobbin et al., 
2002; Robben et al., 2004). This strain difference was also 
shown to have downstream effects, as infection of BMM with 
type II parasites resulted in high levels of IL-12 secretion 
compared with infection with type I parasites (Robben et al., 
2004). At present, the T. gondii factors involved in the modula-
tion of the NF-B pathway are not known.
In our experiments, infection with type II strains induces 
a high level of NF-B activation, whereas infection with type 
I or III strains does not. Using F1 progeny from a type II × 
type III cross, we identify a type II gene responsible for 
NF-B activation, GRA15. The protein product of GRA15 
is a novel dense granule protein that is necessary and sufficient 
for p65 nuclear translocation and NF-B–mediated host cell 
transcription. We show that GRA15 activates the NF-B 
pathway independent of MyD88 and TRIF but dependent 
on TRAF6 and the IKK complex. Although GRA15 does 
not affect overall virulence of parasites, it does have more 
subtle phenotypes in vivo, affecting both parasite growth and 
cytokine levels.
RESULTS
Host gene expression analysis shows strain-specific 
activation of the NF-B pathway
We previously generated a large gene expression dataset from 
human foreskin fibroblasts (HFFs) infected with type I, II, or 
III T. gondii strains (Saeij et al., 2007). In our dataset analysis, 
we focused on the human genes that were differentially regu-
lated by type II strain infection because published data indi-
cated that type II strains might induce more NF-B nuclear 
translocation than type I strains (Dobbin et al., 2002; Robben 
et al., 2004). If T. gondii strains differ in the activation of the 
NF-B pathway, this should lead to differences in expression 
of genes with NF-B transcription factor binding sites 
(TFBSs) in their promoters. 105 genes were found to be more 
than twofold up-regulated in type II infections compared 
with type I and type III infections (Fig. S1 A). Analysis of 
TFBS in the regulatory elements of these genes revealed en-
richment of NF-B TFBS in their promoters (Fig. S1 B), and 
a network analysis of molecular relationships between the 
products of these 105 genes resulted in high scores for two 
networks whose central factors were the transcription factor 
NF-B (network 1) and IL1/PTGS2(COX-2) (network 2). 
IL1 and COX-2 are also regulated by NF-B (Newton 
et al., 1997; Vallabhapurapu and Karin, 2009). These data sug-
gest that there is at least one polymorphic locus between type II 
and type I/III strains that modulates the NF-B pathway.
We also looked for polymorphic loci between type II and 
type III strains that modulate host gene expression using 
quantitative trait locus analysis of human gene expression levels 
subsequent proteasomal degradation. The NF-B complex is 
then free to enter the nucleus where it can induce expression of 
specific genes that have NF-B-binding sites in their promoters.
Many pathogens have developed strategies to modulate 
the host NF-B pathway (Tato and Hunter, 2002). Several 
bacteria and viruses inhibit NF-B activation and its resultant 
recruitment and activation of immune cells, resulting in en-
hanced survival of the pathogen. Other pathogens induce 
NF-B activation, which inhibits apoptosis, an important de-
fense against intracellular pathogens, and increases cell migra-
tion, thereby recruiting new cells to infect. Furthermore, 
NF-B–mediated inflammation leads to tissue damage, al-
lowing pathogens to cross tissue barriers. Thus, depending on 
the host, pathogen, and site of infection, an active NF-B 
pathway can benefit either the host or the pathogen.
Mice deficient in some NF-B family members have in-
creased susceptibility to T. gondii, indicating the importance 
of this pathway in pathogen resistance (Mason et al., 2004). 
C-Rel/ mice are highly susceptible to the acute stage of 
T. gondii i.p. infection, which can be rescued solely by treatment 
with IL-12, indicating that a major role of NF-B in resis-
tance to T. gondii is the induction of IL-12 secretion (Mason 
et al., 2004). IL-12 is a major mediator of the proinflamma-
tory Th1 response development, and the major cause of 
chronic phase death in mice lacking RelB, p52, or the IB 
protein Bcl-3 is also a deficient T cell response (Mason et al., 
2004). Although it is clear that the NF-B pathway is impor-
tant for an adequate response to T. gondii infection, the mice 
used in these studies all lack a particular NF-B subunit in 
every cell of their bodies, and it is currently unknown what 
the role of NF-B is in specific cell types, such as those di-
rectly infected with T. gondii.
Evidence currently exists for both inhibition and activa-
tion of the NF-B pathway in host cells by T. gondii. Less than 
6 h after infection, a type I strain was shown to block the 
nuclear translocation of p65 and the in vitro binding of 
NF-B subunits to DNA (Butcher et al., 2001; Shapira et al., 
2002; Kim et al., 2004). Induction of IL-12 in response to 
TNF or LPS stimulation was also reduced (Butcher et al., 
2001; Kim et al., 2004). This inhibition of the NF-B path-
way was dependent on active invasion by live parasites 
(Butcher and Denkers, 2002). After >6 h of infection, inhibi-
tion of p65 nuclear translocation and in vitro DNA binding 
was no longer observed (Kim et al., 2004; Leng et al., 2009). 
However, chromatin immunoprecipitation experiments showed 
that the in vivo binding of p65 to the TNF promoter was 
blocked even at late time points (Leng et al., 2009). Other 
groups, however, have shown that NF-B is activated by a 
type I strain of T. gondii, and that this activation is necessary 
for the inhibition of apoptosis (Molestina et al., 2003; Payne 
et al., 2003; Molestina and Sinai, 2005b). A consistent obser-
vation has been the phosphorylation and ubiquitination of 
IB upon T. gondii infection, although it is unclear what 
effect this has on the nuclear translocation of NF-B and 
transcription of downstream genes (Butcher et al., 2001; 
Molestina et al., 2003; Shapira et al., 2005). All of these studies 
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increased p65 in the nucleus, indicating that activation is not 
caused by a secreted host factor or a contaminant in the me-
dium. Activation of p65 translocation after infection with 
type II strains was not inhibited by previous infection with 
type I or type III strains, demonstrating that this translocation 
is a result of specific activation by type II parasites rather than 
inhibition by type I/III parasites (Fig. 1, C and D; and not 
depicted). We have observed the activation of NF-B p65 
nuclear translocation by type II parasites in 293T cells, HeLa 
cells, mouse BMM, RAW264.7 murine macrophages, mouse 
embryonic fibroblasts (MEFs), and rat embryonic fibroblasts 
(see Fig. 3; and not depicted).
Type I parasites do not inhibit NF-B activation
Although we observed that a type I strain does not inhibit 
p65 nuclear translocation in a co-infection with a type II 
strain, previous studies have shown that in mouse macro-
phages, infection with type I parasites can inhibit the activa-
tion of NF-B in response to LPS or TNF (Butcher et al., 
2001; Shapira et al., 2002; Kim et al., 2004). To further inves-
tigate if type I parasites can inhibit NF-B translocation, we 
infected BMM with type I parasites for 1 or 18 h, stimulated 
the cells with LPS or TNF, and measured the translocation of 
p65 to the nucleus by IF (Fig. 2 A). In uninfected cells, both 
LPS and TNF stimulation induced the translocation of p65 
subunits to the nucleus. Prestimulation with LPS inhibited 
later LPS-induced translocation, as the activation of Toll-like 
receptor pathways induces negative-feedback mechanisms to 
inhibit further signaling (Lang and Mansell, 2007; Wang et al., 
2009). However, preinfection with type I parasites did not inhibit 
LPS- or TNF-stimulated translocation at early or late time 
points after infection. In fact, preinfection with T. gondii led to 
higher levels of p65 translocation after LPS stimulation, per-
haps as a result of increased TLR4 expression (Kim et al., 2004).
To test whether TNF-stimulated NF-B–mediated tran-
scription can be inhibited by type I parasites, we used a 293 
NF-B reporter cell line that expresses GFP upon NF-B 
activation. Infection of this reporter cell line with type II para-
sites results in high levels of GFP in infected cells (Fig. S9 A). 
We added type I parasites to these cells for 45 min, stimulated 
the cells with TNF, and measured GFP levels of infected and 
uninfected cells by microscopy (Fig. 2 B). After 4 h of stimula-
tion, both infected and uninfected cells had varying levels of 
of cells infected with 19 different F1 progeny from II × III 
crosses. We identified 3,188 human cDNAs that were regu-
lated by a specific T. gondii genomic locus (Saeij et al., 2007). 
1,176 of these human cDNAs were regulated by a locus on 
chromosome VIIb. The T. gondii polymorphic ROP16 kinase 
resides on this chromosome and, via its strain-specific activa-
tion of STAT3/6, is responsible for the differential expression 
of many of the genes that are regulated by a chromosome 
VIIb locus (Saeij et al., 2007). Loci on chromosome X also 
influenced the expression of 563 human cDNAs. To discover 
if these cDNAs are regulated by a common transcription fac-
tor, we determined if any TFBSs were enriched in the pro-
moters of genes that are differentially modulated by F1 
progeny with a type II allele versus a type III allele at each 
chromosome X marker. At many markers, the expression of 
genes with NF-B TFBS in their promoters was enriched in 
F1 progeny with a type II genotype, suggesting that a T. gondii 
factor responsible for strain differences in NF-B activation 
resides on chromosome X (Fig. S1 C). Additionally, network 
analysis of molecular relationships between the 563 genes that 
were significantly influenced by a chromosome X locus and 
their gene products resulted in high scores for two networks, 
one of which had the transcription factor NF-B as its cen-
tral factor (Fig. S1 C). We therefore hypothesized that a poly-
morphic T. gondii locus on chromosome X contributes to 
differential regulation of the host NF-B pathway by type II 
and type I/III strains.
Toxoplasma type II parasites activate NF-B
To investigate modulation of the NF-B pathway by T. gondii, 
we infected HFFs with type I, II, or III T. gondii strains for 
1–24 h and measured nuclear translocation of the NF-B p65 
subunit by immunofluorescence (IF). Starting after 4 h of in-
fection and continuing until at least 24 h of infection, many 
cells infected with a type II strain contained high levels of p65 
in their nucleus, whereas a type I or a type III strain did 
not induce translocation of high levels of p65 to the nucleus 
(Fig. 1 A and B; and not depicted). We have observed the 
translocation of p65 by infection with various type II strains, 
including ME49, Pru, DAG, or Beverley, and the absence of 
high levels of p65 translocation after infection with both 
RH or GT1 type I strains and CEP or VEG type III strains. 
Uninfected HFFs surrounding infected HFFs did not contain 
Figure 1. T. gondii strains differ in the activation of NF-B. HFFs were infected with T. gondii strains for 18–24 h, fixed, and stained with –NF-B 
p65 (red) and Hoechst dye (blue). Shown are infection with a type II (GFP) strain (A) or a type III (GFP) strain (B), and HFFs coinfected with a type I (non-
GFP, arrow) and a type II (GFP) strain of T. gondii (C, brightfield; D, IF). Cells infected with only type I parasites (arrowhead) do not contain nuclear NF-B. 
This experiment has been repeated >10× with similar results. Bars, 10 µm.
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stimulation were not identical; however, genes with NF-B 
TFBS in their promoters or belonging to an NF-B–related 
pathway were equally enriched in those two samples (Fig. 2 C). 
We therefore conclude that type I parasites do not inhibit 
TNF- or LPS-stimulated NF-B p65 translocation or TNF-
stimulated NF-B–mediated transcription, but they may be 
able to modulate other pathways or host cell transcription 
factors which are important for expression of a small subset of 
TNF stimulated genes.
A T. gondii genomic locus on chromosome X mediates 
strain-specific activation of NF-B
To find the T. gondii genomic regions mediating the type II 
versus type I/III strain-specific difference in activation of 
NF-B, we infected HFFs with 27 F1 progeny derived from 
crosses between type II and type III strains and measured NF-B 
GFP, with some cells containing almost no GFP and <50% of 
cells having a high level of GFP. However, the distribution of 
GFP intensity in the populations of infected and uninfected 
cells was not significantly different. Unstimulated cells, either 
infected or uninfected, had negligible levels of GFP (un-
published data). Type I parasites also did not inhibit NF-B–
mediated transcription of luciferase in a 293 NF-B luciferase 
reporter cell line (unpublished data).
To investigate if type I preinfection might inhibit tran-
scription of specific subsets of NF-B–regulated genes, we 
infected HFFs with a type I strain for 18 h or left cells un-
infected and subsequently stimulated the cells with TNF for 
6 h. We then performed gene expression analysis using 
Affymetrix microarrays. Comparing the expression data to 
uninfected HFF expression data, the genes regulated by TNF 
stimulation alone and type I preinfection followed by TNF 
Figure 2. Type I parasites do not inhibit 
NF-B activation. (A) C57BL/6 BMMs were 
untreated, stimulated with 100 ng/ml LPS or 
20 ng/ml mouse TNF, or infected with type I 
parasites (MOI = 2) for 1 h (top) or 18 h (bot-
tom). Cells were then restimulated for 30 min 
with LPS or 45 min with TNF, fixed, and stained 
with –NF-B p65 and Hoechst dye. The in-
tensity of nuclear NF-B p65 was quantitated 
in at least 10 cells per treatment. Values repre-
sent the fold induction of nuclear p65 levels 
over uninfected unstimulated cells. This ex-
periment was done once in BMM. A second 
experiment of HFFs infected with type I para-
sites and subsequently stimulated with TNF 
yielded similar results. Error bars represent 
standard deviation. (B) A 293 NF-B GFP re-
porter cell line was plated on coverslips and 
infected with type I parasites (MOI = 1–2) for 
45 min and then stimulated with 100 ng/ml 
human TNF for 4 h, fixed, and stained with  
-SAG1 (red). Bars, 10 µm. The GFP intensity was 
quantitated for at least 30 infected cells and 
30 uninfected cells (bottom; n.s. = not signifi-
cant, two sample Student’s t tests). Horizontal 
bars represent the mean GFP intensity of cells. 
This experiment was performed twice, with the 
same qualitative results. Similar results were 
also obtained with a 293T NF-B luciferase 
reporter cell line. (C) Microarray analysis was 
done on HFFs preinfected with a type I strain 
(MOI = 7.5) for 18 h, or left uninfected, and 
subsequently stimulated with 20 ng/ml human 
TNF for 6 h. Genes were preranked for both 
samples by the difference in expression, as 
compared with uninfected untreated HFFs, and 
GSEA was used to determine whether genes 
with NF-B TFBS in their promoters or belong-
ing to NF-B–related canonical pathways 
were enriched in either or both samples. False 
discovery rate q-values <0.25 were considered 
significant. One array per strain and treatment 
was done.
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contains 45 predicted type II genes 
(ToxoDB.org, v6.0).
To identify the T. gondii gene 
responsible for NF-B activation, 
we used a candidate gene approach. 
From the 45 predicted type II genes, 
the SAG2CDXY (SRS49a/b/c/d) 
locus was excluded, as a type II strain 
with this locus deleted still activates 
NF-B (Saeij et al., 2008; unpub-
lished data). Our first criterion for a 
protein able to interface with the 
host cell and modulate host cell sig-
naling was the presence of a signal 
sequence. Of the 41 remaining genes, 
17 are predicted to have a signal 
sequence. Of these 17 genes, four 
(ROP8, ROP2A, GRA6, and 63.m00001) were consistently 
expressed in tachyzoites in infected macrophage cells, as de-
termined by T. gondii microarrays (unpublished data). Our top 
candidate genes (ROP2A, GRA6, and 63.m00001) were then 
tested by adding a type II C-terminal HA-tagged copy of the 
candidate gene, including at least 1,500 bp of the putative 
endogenous promoter, into a type I and/or III strain and as-
saying whether these transgenic type I/III strains activate 
NF-B. Type I and III strains stably expressing a copy of 
63.m00001 activated NF-B in HFFs, whereas strains ex-
pressing a copy of GRA6 or ROP2 did not, indicating that 
63.m00001, hereafter referred to as GRA15, is the locus on 
chromosome X which mediates the strain-specific activation 
of NF-B (Fig. 3 and Fig. S3).
activation by IF. Only HFFs infected with F1 progeny having 
type II alleles for the genetic markers ROP2 and GRA6 at the 
right end of T. gondii chromosome X contained nuclear NF-B 
p65 (Fig. S2). Thus, the genomic region in the vicinity of ge-
netic markers ROP2-GRA6 harbors one or more genes in-
volved in the activation of NF-B. We developed new RFLP 
markers to more accurately define the place of recombination 
in progeny that are recombinant for chromosome X around 
ROP2 and GRA6 and therefore limit the genomic region in-
volved in the activation of NF-B and the number of possible 
candidate genes. With these new markers, genotyping of 
STE7 refined the 3 boundary of the region and geno-
typing of S26 refined the 5 boundary of the region (Fig. S2). 
The refined region between the markers SAG2E and RC4 
Figure 3. GRA15 mediates NF-B p65 
translocation. (A) HFFs were infected with 
T. gondii strains for 18 h, fixed, and stained 
with –NF-B p65 (red), -SAG1 (green), 
and Hoechst dye (blue). Bars, 10 µm. (B) The 
amount of p65 in the nucleus was quanti-
tated in at least 15 HFF cells for each strain. 
Asterisks indicate significantly higher levels 
of nuclear p65 compared with uninfected 
cells (*, P < 0.001, two sample Student’s  
t tests). (C) Mouse BMDMs (BALB/c) were 
infected with T. gondii strains for 24 h, fixed, 
and stained with –NF-B p65 (red), -
SAG1 (green), and Hoechst dye (blue). Bars, 
10 µm. (D) The level of nuclear p65 in in-
fected cells was quantitated in at least 12 
infected cells per strain. Asterisks indicate 
significantly higher levels of nuclear p65 
compared with uninfected cells (*, P < 
0.005, two sample Student’s t tests). One 
replicate experiment was done in both HFFs 
and mouse BMDM with similar qualitative 
results. Horizontal bars represent the mean 
nuclear p65 intensity over all cells.
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resulting in a significant difference in 
the average nuclear p65 of type II–
infected cells compared with type I 
or type III–infected cells (Fig. 3, A 
and B). Type I (but not type III)–in-
fected cells did have significantly 
more nuclear NF-B p65 than unin-
fected cells. Type I and type III strains 
engineered to stably express a type II 
HA-tagged copy of GRA15 (type I 
GRA15II and type III GRA15II) ac-
tivated NF-B (Fig. 3, A and B). As 
with type II–infected cells, a subset 
of type I GRA15II–infected cells had 
very high levels of nuclear NF-B, 
and the average nuclear p65 was sig-
nificantly higher in these cells com-
pared with type I–infected cells. A 
time-course experiment showed that 
this activation occurred starting 4 h 
after infection (Fig. S4).
To determine if type II GRA15 
was necessary for NF-B p65 trans-
location in host cells, we generated 
type II GRA15KO strains (Fig. S5). 
Removal of the GRA15 locus abolished p65 translocation by 
type II parasites in host cells, eliminating the subset of in-
fected cells with a high level of nuclear p65 (Fig. 3, A and B). 
The level of nuclear p65 in cells infected with type II 
GRA15 mediates NF-B p65 translocation
We quantified the nuclear p65 IF signal of cells infected with 
type I, II, or III strains, confirming that a subset of type II– 
infected cells had a high level of nuclear p65 (intensity >800), 
Figure 4. GRA15 activates NF-B–
mediated transcription. HFFs or MEFs were 
infected for 18–24 h with type II, type II 
GRA15KO, type I, type III, type I GRA15II, or 
type III GRA15II T. gondii strains, and host cell 
gene expression was analyzed by Affymetrix 
microarrays. At least two arrays were done 
per strain in HFFs and one array was done 
per strain in MEFs. (A) The top three enriched 
known TFBSs from GSEAs comparing type II 
versus type II GRA15KO and type I/III GRA15II 
versus type I/III infections are shown. (B) For 
the 146 genes that are defined as core 
GRA15-regulated genes, mean log2 gene 
expression values were median centered, 
genes were clustered by hierarchical cluster-
ing, and a heat map is presented. The com-
plete set of genes is listed in Supplemental 
data 2. (C) Ingenuity pathway analysis was 
done for these 146 genes. The top two scor-
ing networks are shown. (D) In MEF arrays, 32 
genes have the same expression level in un-
infected unstimulated WT and p65/ cells 
and are regulated by GRA15. For these genes, 
log2 expression values were median centered, 
genes were clustered by hierarchical cluster-
ing, and a heat map is shown. The complete 
set of genes is listed in Supplemental data 2.
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In WT MEFs, we found 32 genes to be core GRA15-regulated 
genes (more than twofold different in type II vs. type II 
GRA15KO or type I GRA15II vs. type I infections and simi-
lar expression level in uninfected unstimulated WT and 
p65/ MEFs). Of these 32 genes, only three are also GRA15 
regulated in p65/ host cells. This data indicates that the 
majority of host cell transcription induced by GRA15 was 
activated via the canonical p65/p50 NF-B heterodimer; 
however, it is possible that a small subset of genes was acti-
vated by other NF-B subunits, such as c-Rel/p50 dimers, or 
other transcription factors.
GRA15 is a polymorphic secreted dense granule protein
The GRA15 coding region is predicted to be 1,908 bp in 
type I and III strains, but only 1,653 bp in type II strains, as a 
GRA15KO parasites was not significantly different from the 
level in uninfected cells (Fig. 3 B). To confirm that GRA15 is 
responsible for the NF-B activation phenotype, we trans-
fected GRA15II back into a type II GRA15KO strain. NF-B 
p65 nuclear translocation was rescued in this type II GRA15KO 
GRA15II strain (Fig. 3, A and B). Additionally, a type I 
GRA15KO GRA15II strain activated translocation of p65, 
and infection with this strain or a type I GRA15II strain did 
not activate significantly different levels of nuclear p65, con-
firming that the type II copy of GRA15 alone was sufficient 
for the nuclear translocation of p65 by type I strains of T. gon-
dii. Similarly, in mouse BMM, infection with type II strains, 
but not type I/III strains, activated a high level of p65 nuclear 
translocation. This activation was also a result of the type II 
GRA15 gene (Fig. 3, C and D).
To examine if p65 was the only NF-B family subunit 
activated by GRA15, we infected HFFs with type I GRA15II 
parasites for 24 h and examined p50, p52, RelB, and c-Rel 
nuclear localization by IF (Fig. S6). Only p50 was specifically 
and significantly translocated to the nucleus by type I GRA15II 
strains (Fig. S6 A). However, there was a significant increase in 
levels of nuclear c-Rel upon infection with both type I and 
type I GRA15II strains (see Fig. S6 D).
GRA15 activates NF-B–mediated transcription
To determine if the nuclear NF-B p65 triggered by GRA15II 
is transcriptionally active, we infected HFFs with type II, type 
II GRA15KO, type I, type I GRA15II, type III, or type III 
GRA15II T. gondii and hybridized RNA from the infections 
to Affymetrix human genome arrays to determine host cell 
gene expression. The expression of genes with NF-B TFBS 
in their promoters and gene products belonging to an NF-B–
related pathway was enriched in type II versus type II 
GRA15KO infections and type I/III GRA15II versus type I/
III infections (Fig. 4 A and Supplemental data 1). 146 tran-
scripts were strongly regulated by GRA15, regardless of the 
T. gondii strain genetic background, and we defined these 
genes as core GRA15-regulated genes (Fig. 4 B). Network 
analysis of molecular relationships between these 146 genes 
and their gene products also demonstrated an enrichment of 
genes involved in cytokine and NF-B signaling (Fig. 4 C).
Type I T. gondii parasites also activate NF-B p65 translo-
cation in HFFs, although at a much lower level than type II 
strains (Fig. 3). Microarray analysis confirmed that a type I strain 
can cause the activation of NF-B–mediated transcription. 
The expression of genes with NF-B TFBS in their promot-
ers and gene products belonging to an NF-B–related path-
way was enriched in type I–infected HFFs over uninfected 
HFFs (Supplemental data 1). This activation is not dependent 
on GRA15; the expression of NF-B regulated genes was 
enriched in a type I GRA15KO infection compared with 
uninfected cells, and not in a type I infection compared with 
a type I GRA15KO infection (unpublished data).
We also infected WT and p65/ MEFs with type II, type 
II GRA15KO, type I, or type I GRA15II T. gondii strains and 
analyzed host cell gene expression by microarray (Fig. 4 D). 
Figure 5. GRA15 is a secreted dense granule protein. (A) Parasites 
expressing GFP and an HA-tagged copy of GRA15II were added to HFFs for 
5 min to allow attachment and evacuole formation. Cells were then fixed 
and stained with -HA (red), -ROP1 (green), and Hoechst dye (blue). The 
HA tag is present with ROP1 in evacuoles, indicating that GRA15 can be 
secreted into the host cell. This experiment was repeated once with cyto-
chalasin d–treated parasites with the same results. (B) Co-infection of type 
I (non-GFP) and type I GRA15II-HA (GFP) parasites, done once. Arrows indi-
cate HA staining on the PVM of a non-GFP vacuole. (C) Co-staining of 
GRA15II-HA with a dense granule marker, GRA7, shows colocalization of 
HA staining and GRA7 in both the dense granules and the PV. Conversely, 
costaining of GRA15II-HA with a rhoptry marker, ROP1, shows almost no 
overlap between the HA tag and the rhoptries. Co-staining was done once, 
but the same GRA15II-HA staining pattern has been observed in more than 
five independent experiments. Bars, 5 µm.
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sequence contains a frameshift mutation at base 872. This 
frameshift leads to the mutation of a stretch of 22 amino acids 
(2 remain conserved), followed by a premature stop codon, 
truncating the protein to 312 amino acids, instead of 635 
amino acids. The type I/III and II protein sequences differ 
most strikingly at the 84–amino acid indel near the C termi-
nus of the protein. Besides this indel, five other amino acids 
are polymorphic between types I/III and II and one other 
single amino acid is inserted or deleted (Fig. S7).
We next looked by IF at the localization of GRA15 in the 
parasite and infected host cells. To determine if GRA15 was 
secreted into the host cell, we performed evacuole staining on 
a 5-min type I GRA15II-HA infection of HFF cells using an 
antibody against the HA tag (Fig. 5 A). HA staining is clearly 
present in evacuoles, partially colocalizing with evacuoles 
containing rhoptry proteins, indicating that GRA15 is a se-
creted protein. Evacuoles containing GRA15 can also be seen 
after attachment of cytochalasin d–treated parasites (unpub-
lished data). In parasitophorous vacuoles (PVs), costaining of 
the GRA15II-HA protein with either a rhoptry marker, ROP1, 
result of either an insertion or deletion (indel; ToxoDB.org, 
v6.0). An intron is predicted in the type I and type III copies, 
very close to the indel. We sequenced the region around this 
indel of both type I and type II cDNA. Neither strain was 
found to have an intron in this region, and the indel was con-
firmed. To determine the full transcript of GRA15II, we per-
formed 5 and 3 rapid amplification of cDNA ends (RACE). 
Two GRA15II transcription start sites were found, one at 
508 to 504 bp upstream of ATG and one at 277 bp up-
stream of ATG. Three polyadenylation sites were found, at 
+930, +992, and +1,144 bp downstream of the stop codon.
ToxoDB.org currently contains sequences from one strain 
for each of the three North American/European clonal lin-
eages of Toxoplasma: GT1 (type I), ME49 (type II), and VEG 
(type III). The genomic sequences of strains within the same 
lineage are thought to be very similar; however, we sequenced 
the GRA15 locus from RH (type I), Pru (type II), and CEP 
(type III) strains as well, three other strains which we have 
used in our experiments. Although Pru and CEP have an 
identical sequence to ME49 and VEG, respectively, the RH 
Figure 6. GRA15 activity affects total levels of phospho-IB but not PVM-associated phospho-IB. (A) HFFs were infected with T. gondii 
strains for 24 h or stimulated with TNF for indicated times, and cell lysates were collected, run on an SDS-PAGE gel, and Western blotted for phospho-
IB, total IB, SAG1 (parasite loading control), and GAPDH (host cell loading control). From the total IB blot, the fraction of phosphorylated IB 
was determined by comparing the intensity of the upper band (phosphorylated form) to the total intensity of the lower and upper band. This experiment 
was repeated once with type I and type I GRA15II strains only with similar results. (B) HFFs were coinfected with type I (non-GFP) and type II (GFP) para-
sites, fixed, and stained with –phospho-IB (red) and Hoechst dye (blue). A type I PVM (non-GFP, arrowhead) and a type II PVM (GFP, arrow) are indi-
cated. Bar, 5 µm. (C) HFFs were infected with T. gondii strains expressing GFP for 24 h, fixed, and stained with –phospho-IB (red) and Hoechst dye 
(blue). This experiment has been done three times with similar results. Bars, 1 µm.
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and NF-B–mediated gene expression is severely decreased 
(Molestina and Sinai, 2005b). To determine if the accumula-
tion of phospho-IB on the PVM correlated with NF-B 
activation, we infected HFFs with T. gondii strains and stained 
infected cells with a phospho-IB antibody. Although infec-
tion with type II parasites activated NF-B to a much greater 
extent and led to higher levels of total phospho-IB com-
pared with type I parasite infection, in a mixed infection of 
type I (non-GFP) and type II (GFP) T. gondii, phospho-IB 
accumulated almost exclusively on type I vacuoles (Fig. 6 B). 
We also found that the accumulation of phospho-IB at the 
PVM was independent of GRA15, as both type I and type I 
GRA15II PVMs accumulated phospho-IB, and neither 
type II nor type II GRA15KO PVMs accumulated visible 
levels of phospho-IB (Fig. 6 C). Phospho-IB also did 
not accumulate on type III PVMs (Fig. 6 C). We conclude 
that the accumulation of PVM-associated phospho-IB is 
specific to type I parasites and is not correlated with the over-
all level of NF-B activation in the host cell.
GRA15 activation of NF-B is dependent on the IKK 
complex and TRAF6 but independent of MyD88 and TRIF
BLAST and Pfam searches for proteins with similar amino 
acid sequences or domains to GRA15II returned no signifi-
cant results, providing no clues to the mechanism of GRA15 
NF-B activation (Altschul et al., 1990; Finn et al., 2008). To 
start to answer this question, we determined which compo-
nents of the NF-B signaling pathway were necessary for 
GRA15 activity. When NF-B is activated, IB proteins are 
phosphorylated and then degraded by the proteasome. We 
previously determined that GRA15 leads to the phosphory-
lation of IB (Fig. 6), and to determine if GRA15 activity is 
dependent on the proteasome, we pretreated cells with MG132, 
a proteasomal inhibitor. Our results show that activation of 
or a dense granule marker, GRA7, showed colocalization of 
GRA15II-HA with GRA7, with almost no overlap between 
the HA tag and ROP1 (Fig. 5 C). GRA15 staining overlaps 
GRA7 staining in the dense granules and within the PV. 
GRA15 also localizes to the outside of the PV membrane 
(PVM), and in a co-infection of type I (non-GFP) and type I 
GRA15II-HA (GFP) parasites, HA staining can be seen local-
ized in the PVM and on the outside of the PVM of a parasite 
expressing GRA15II-HA (GFP), as well as on the outside of 
the PVM of a parasite not expressing GRA15II-HA (Fig. 5 B), 
which is consistent with dense granule localization. We there-
fore conclude that GRA15 is a dense granule protein.
GRA15 affects total levels of phospho-IB but does not 
affect PVM-associated phospho-IB
The nuclear translocation of NF-B transcription factor sub-
units is dependent on the phosphorylation and degradation 
of an inhibitory protein, IB. We determined if GRA15 af-
fected the overall levels of phospho-IB in infected cells by 
Western blotting and quantified the fraction of phosphory-
lated IB compared with the total level of IB (Fig. 6 A). 
Infection with a strain of T. gondii expressing GRA15II led to 
an increase in the fraction of total IB that was phosphory-
lated, although not to the extent of TNF-induced levels. This 
indicates that GRA15 activates NF-B through the phos-
phorylation of IB.
Previously, a type I T. gondii protein extract was found to 
have IB-phosphorylating activity in vitro (Molestina et al., 
2003). There is also evidence that this kinase activity can 
occur in vivo, as PVM-associated phospho-IB can still be 
observed in infected IKK-/ double knockout MEFs 
(Molestina and Sinai, 2005a). However, in these IKK-/ 
double knockout cells, after type I T. gondii infection NF-B 
does not translocate to the nucleus or bind to DNA in vitro, 
Figure 7. GRA15 activity is dependent on IKK- and TRAF6 and independent of MyD88 and TRIF. Cells were infected with type I GRA15II or 
type I parasites for 4 h, stimulated with 20 ng/ml TNF for 1 h, or left unstimulated (US) and uninfected (UI). Cells were fixed and probed with an –NF-B 
p65 antibody and mean nuclear staining was measured. (A) HFF cells were preincubated with media containing 20 ng/ml MG-132 proteasome inhibitor 
before infection and TNF stimulation. (B–D) The activity of GRA15II in the absence of different components of the NF-B pathway was assayed. (B) IKK-
/ MEFs. (C) TRAF6/ MEFs. (D) MyD88//TRIF/ BMMs. These experiments were repeated at least two times and quantification was performed on a 
representative experiment for each factor assayed. Asterisks (*) indicate data are significantly different (P-value < 0.05, Student’s t test), and n.s. indicates 
data are not significantly different. Horizontal bars represent the mean nuclear p65 intensity over all cells.
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GRA15 affects IL-12 production in vitro
In vitro infection of macrophages with different strains of 
T. gondii results in different levels of IL-12p40 secretion, with 
type II strains inducing much higher levels of IL-12p40, and 
some of this variation has been suggested to be a result of 
strain differences in NF-B activation (Robben et al., 2004; 
Kim et al., 2006; Saeij et al., 2007). To examine the role of 
GRA15-mediated NF-B activation in the induction of 
IL-12p40 secretion, mouse BMMs were infected with type I, 
type I GRA15II, type II, or type II GRA15KO T. gondii, and 
levels of IL-12p40 in the supernatant were determined by 
cytokine ELISA (Fig. 9 A). As expected, type I–infected 
BMMs secrete a low level of IL-12p40 that is not signifi-
cantly higher than the level secreted by uninfected cells, 
whereas type II induces a high level of IL-12p40 secretion. 
When GRA15 is removed from the type II strain, IL-12p40 
secretion decreases more than sixfold, implying a consider-
able role for this gene product in modulating host cell IL-12 
signaling (P = 0.001, Student’s t test). Similarly, the introduc-
tion of GRA15II in a type I strain leads to a significant 
increase in IL-12p40 secretion by BMM (P = 0.008, Stu-
dent’s t test). IL-12p70 secretion was also higher after type II 
infection, compared with a type I infection, and partially 
NF-B by GRA15 required functional proteasomal degrada-
tion (Fig. 7 A). IB proteins are normally phosphorylated by 
the IKK complex, consisting of IKK-, IKK-, and IKK- 
(NEMO). IKK- is a regulatory subunit in the complex, 
whereas the  and  subunits are active kinases. IKK- has 
greater kinase activity than IKK- and is the principal kinase 
responsible for the phosphorylation of IB (Ghosh and Karin, 
2002; Li and Verma, 2002). In WT MEFs, a type I GRA15II  
strain induces a 3.4-fold increase in nuclear p65 compared with 
uninfected cells. However, in IKK-/ MEFs, this increase is 
only 1.9-fold (Fig. 7 B). Many pathogens activate NF-B via 
TLR agonists, and TLR signaling is mediated by the MyD88 
and TRIF adaptor proteins. However, GRA15 is able to acti-
vate p65 nuclear translocation in MyD88/TRIF double knock-
out cells, indicating that it is not just a TLR ligand (Fig. 7 D). 
GRA15-mediated p65 activation is also not dependent on 
RIP1 but is dependent on TRAF6 (not depicted and Fig. 7 C). 
Thus GRA15 appears to modulate NF-B at a specific step in 
the pathway downstream of MyD88 and TRIF but upstream 
of, or in a complex with, TRAF6 and IKK proteins.
GRA15 expressed in Hela cells is sufficient  
to activate NF-B
We wanted to determine whether GRA15II alone is sufficient 
to activate p65 nuclear translocation or if other T. gondii se-
creted factors that are common to all type I, II, and III strains 
are also needed for this process. When we transiently trans-
fected HeLa cells with a vector expressing the type II copy of 
GRA15 N-terminally fused with GFP, the nuclei of trans-
fected GFP-positive cells contained p65, whereas the nuclei of 
nontransfected GFP-negative cells in the same culture did not 
(Fig. 8 A). The level of this nuclear localization is equivalent 
with activation by intracellular type I GRA15II parasites (Fig. 
8 B). Expression of 55.m04955, an unrelated T. gondii protein, 
or Mob1A, a human protein present in the original vector, did 
not induce p65 translocation, indicating that this NF-B acti-
vation is not the result of cell stress from protein overexpres-
sion (Fig. 8 A). GRA15II expression alone is therefore sufficient 
to recapitulate the induction of p65 nuclear translocation.
GRA15 affects in vitro parasite growth
To assay the effect of GRA15 on in vitro parasite growth, we 
infected monolayers of fibroblasts with type I, type I GRA15II, 
type II, or type II GRA15KO parasites, allowed the parasites 
to grow for 4–7 d, and then quantified the area of plaques 
formed on the monolayers. In HFF host cells, a type II 
GRA15KO strain formed significantly larger plaques than a 
type II strain (P = 0.002, Student’s t test), and a type I strain 
formed significantly larger plaques than a type I GRA15II 
strain (P = 0.024, Student’s t test; Fig. S8 A). However, in MEF 
host cells, type II and type II GRA15KO strains did not make 
significantly different sized plaques (P = 0.841, Student’s t 
test), and the same was true of type I and type I GRA15II 
strains (P = 0.371, Student’s t test; Fig. S8 A). This data indicates 
that GRA15 inhibits in vitro parasite growth in human fibro-
blasts but not mouse fibroblasts.
Figure 8. GRA15 expression alone is sufficient to activate NF-B 
in HeLa cells. (A) HeLa cells were transfected with GRA15II, an unrelated 
T. gondii gene (55.m04955), or an unrelated human gene (Mob1A) fused 
to GFP. Cells were then fixed and stained with –NF-B p65 (red) and 
Hoechst dye (blue). All cells expressing GRA15II-GFP contain activated NF-
B p65, whereas cells expressing 55.m04955-GFP or Mob1A-GFP do not. 
Nontransfected non-GFP cells in the same culture also have no nuclear 
NF-B p65. This experiment was repeated two more times with the same 
results. (B) HeLa cells were infected with type I GRA15II or type I parasites 
for 24 h, fixed, and stained with –NF-B p65 (red) and Hoechst dye 
(blue). Cells infected with a type I GRA15II strain contain comparable 
amounts of nuclear NF-B p65 to transfected cells. This experiment was 
repeated a second time with similar results. Bars, 10 µm.
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GRA15 affects in vivo parasite growth  
and cytokine production
To assay the effect of GRA15 on parasite virulence, we in-
fected C57BL/6 or BALB/c mice by i.p. injection with 5,000 
tachyzoites of a type II or a type II GRA15KO strain and 
monitored mouse survival during the acute phase of infection 
(days 0–20; Fig. 9 B). C57BL/6 mice infected with either 
strain succumbed to infection at the same time, between days 
5 and 18 after injection. Additionally, the same percentage of 
mice in each group survived, 40%. BALB/c mice infected 
with either a type II or a type II GRA15KO strain did not die 
after infection.
To determine the effect of GRA15 on in vivo parasite 
burden, BALB/c mice infected i.p. with tachyzoites of either 
a type II or a type II GRA15KO strain that express the en-
zyme luciferase were imaged throughout infection. At day 5 
after infection, mice infected with a type II GRA15KO strain 
had a significantly higher parasite burden than mice infected 
with a type II strain (Fig. 9 C; P = 0.01, Student’s t test). Simi-
larly, expression of GRA15II in a type I strain inhibited in vivo 
parasite growth (Fig. S8 B). Together, these experiments indicate 
dependent on the presence of a type II copy of GRA15 (un-
published data).
The T. gondii polymorphic rhoptry kinase ROP16 also 
affects IL-12 secretion, and previous microarray analyses de-
termined that the expression of many GRA15-regulated 
genes are also strongly affected by a locus on chromosome 
VIIb, where ROP16 resides (Saeij et al., 2007). In these analy-
ses, some genes, such as SOCS-2 and SOCS-3, were regulated 
by loci on both chromosome VIIb and X (Fig. S9 A). 
We wondered if the effect of ROP16 on these genes was 
through modulation of the NF-B pathway. We infected an 
NF-B GFP reporter cell line with a type II strain or a type 
II transgenic strain expressing a type I copy of ROP16. A sig-
nificantly greater percentage of type II–infected cells than 
type II ROP16I–infected cells are GFP positive (P = 1.5 × 107, 
2 test), indicating that in a type II background, a type I copy 
of ROP16 significantly inhibits NF-B activation (Fig. S9 B). 
In an NF-B luciferase reporter cell line, infection with a 
type II ROP16I strain also induced significantly less luciferase 
activity than infection with a type II strain (unpublished data). 
Thus, both GRA15 and ROP16 affect NF-B activity.
Figure 9. GRA15II promotes IL-12 secretion in vitro and affects parasite growth and host cytokine production in vivo. (A) BALB/c BMMs were 
infected with T. gondii strains for 24 h, supernatants were collected, and IL-12p40 levels were determined by cytokine ELISA. These experiments were per-
formed at least three times in BMM using triplicate samples, as well as in RAW264.7 macrophages, all with similar results. (B–D) Mice were infected i.p. 
with tachyzoites of either a type II or a type II GRA15KO strain. (B) C57BL/6 or BALB/c mice were infected with 5,000 tachyzoites and survival of mice was 
monitored. In one experiment, five BALB/c mice were infected per strain, and in three separate experiments, a total of 25 C57BL/6 mice were infected per 
strain. (C) BALB/c mice were infected with parasites that express the enzyme luciferase. 5 d after infection, mice were i.p. injected with luciferin, anesthe-
tized, and the flux (photons/sec/cm2/sr) was determined as a measure of parasite burden. Mice infected with a type II GRA15KO strain had significantly 
greater total flux (p/s) and, therefore, significantly greater parasite burden than mice infected with a type II strain. This burden difference 5 d after infec-
tion was observed in three independent experiments. (D) 1 or 2 d after infection, infected BALB/c mice were euthanized and an i.p. cavity wash was col-
lected for IFN-, IL-12p70, and IL-12p40 cytokine ELISA. On day 2 after infection, mice infected with a type II GRA15KO strain had significantly lower 
levels of IFN- in the i.p. cavity than mice infected with a type II strain (P = 0.05, two-sample Student’s t test). Five mice were infected per strain per day. 
Day 2 cytokine levels were measured in a separate experiment with similar results. Error bars represent standard deviation from one experiment.
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type II infection, and infection with a type I strain does not 
activate detectable GFP or luciferase transcription from an 
NF-B reporter cell line (unpublished data), which is in con-
cordance with another published study (Shapira et al., 2005). 
This low-level activation is also not dependent on GRA15, 
as there is no enrichment in NF-B activation in a type I 
infection over a type I GRA15KO infection. Type III strains 
do not activate any p65 nuclear translocation or NF-B– 
mediated transcription.
Our results agree with previous observations that phos-
phorylated IB accumulates on the PVM upon T. gondii 
type I infection (Butcher et al., 2001; Molestina et al., 2003; 
Shapira et al., 2005). However, levels of PVM-associated 
phospho-IB are not correlated with total levels of phos-
pho-IB or the level of NF-B transcriptional activity in 
the host cell. Phospho-IB is not observed on type II PVMs, 
and, although infection with T. gondii strains expressing GRA15II 
leads to higher total levels of phospho-IB, the presence of 
GRA15 does not affect PVM-associated phospho-IB (Fig. 6). 
A type I T. gondii protein capable of phosphorylating IB 
may play a role in low-level activation of NF-B in type I 
strains (Molestina and Sinai, 2005a). However, it is clear that 
the GRA15 protein in type II strains activates NF-B to a 
much greater extent.
In contrast, some groups have reported that infection 
with type I T. gondii strains inhibits NF-B activation after 
stimulation with the cytokine TNF or the TLR ligand LPS 
(Butcher et al., 2001; Shapira et al., 2002; Kim et al., 2004). 
This inhibition has been observed after <6 h of infection in 
HFFs (Shapira et al., 2005), mouse BMM (Shapira et al., 2002; 
Kim et al., 2004), and thioglycolate-elicited cells (Butcher 
et al., 2001) and was not observed after 6 or 12 h of infection 
in mouse BMM (Kim et al., 2004; Leng et al., 2009). Our ex-
periments confirm that type I T. gondii cannot inhibit LPS-
stimulated NF-B nuclear translocation or TNF-stimulated 
NF-B transcriptional activity at a late time point in infec-
tion (Fig. 2, A and C). But, after a short infection (<5 h), we 
also do not observe inhibition of NF-B p65 nuclear transloca-
tion or NF-B–mediated transcription, contradicting previous 
studies (Fig. 2, A and B). It is true that some infected cells do 
not respond to LPS or TNF stimulation, and this observation 
may have lead to the conclusion that type I strains can inhibit 
NF-B signaling. However, quantification of NF-B p65 
translocation and NF-B reporter transcription in many 
uninfected and infected cells shows that preinfection with 
T. gondii does not alter the response of populations of cells to 
these stimuli.
The GRA15 gene product is a novel T. gondii dense gran-
ule protein that is secreted into the host cell upon invasion 
(Fig. 5), representing the first identified Apicomplexan dense 
granule protein that can modulate host cell signaling path-
ways. Rhoptry proteins have already been identified as para-
site factors that can alter host cell behavior, but our findings 
indicate that dense granule proteins should be viewed as can-
didate factors as well. It is still unclear why only the type II 
copy of GRA15 activates NF-B. Amino acid polymorphisms 
that GRA15 inhibits in vivo parasite growth in both a type I 
and a type II background.
GRA15 affects IL-12 secretion by BMM in vitro, and we 
also assessed whether it affects cytokine secretion in vivo at 
the site of infection. BALB/c mice were infected i.p. with 
tachyzoites of either a type II or a type II GRA15KO strain. 
1 or 2 d after infection, mice were sacrificed, the i.p. cavity 
was washed, and cytokine levels in the wash were determined 
by ELISA. On day 2 after infection, mice infected with a type 
II GRA15KO strain had significantly less IFN- in their i.p. 
cavities than mice infected with a type II strain (Fig. 9 D; 
P = 0.05, Student’s t test). Although differences in IL-12p40 
or p70 were not significant on either day 1 or day 2 because 
of large variations between mice, the average cytokine levels 
in type II GRA15KO–infected mice were consistently lower 
than cytokine levels in type II–infected mice. At these early 
time points, there was not a significant difference in parasite 
load between mice infected with either strain, as determined 
by imaging (unpublished data).
DISCUSSION
The modulation of the NF-B pathway by T. gondii has long 
been an area of debate, with some studies stating that T. gondii 
activates NF-B and others that T. gondii inhibits NF-B 
activation. In this study, we have conclusively shown that the 
three North American clonal lineages of T. gondii differ in 
their activation of the host NF-B pathway; type II strains 
activate a high level of NF-B p65 translocation, whereas 
type I and III strains do not (Fig. 3). Using F1 progeny from 
a type II × type III cross, we found that a locus on chromo-
some X is responsible for this polymorphic phenotype, and 
we identified the novel T. gondii factor GRA15 at this locus 
(Fig. S2). The type II copy of GRA15 (63.m00001) is neces-
sary in type II strains and sufficient in type I and III strains 
for NF-B nuclear translocation and transcriptional activity 
(Figs. 3 and 4; and Supplemental data 1). We have observed 
this activation in a variety of human, mouse, and rat cell 
types, indicating that GRA15’s activity is independent of 
host cell type and species. Additionally, when GRA15II is 
expressed in HeLa cells, it is sufficient to activate NF-B 
(Fig. 8 A).
It had been previously reported that infection with type I 
strains of T. gondii activates NF-B in MEF and Henle 407 
intestinal epithelial host cells (Molestina et al., 2003; Ju et al., 
2009). Careful quantification of IF experiments showed that 
type I strains do slightly activate NF-B p65 translocation, 
but the level of nuclear p65 is much higher in type II– 
infected cells than type I–infected cells (Fig. 3). It is possible 
that other groups have concluded that type I strains do not 
activate NF-B because this activation is so low compared 
with that of LPS or TNF stimulation (Butcher et al., 2001; 
Shapira et al., 2002, 2005). Our IF experiments also showed 
that a type I strain activates c-Rel nuclear translocation, which 
might also affect host cell transcription (Fig. S6). By micro-
array analysis, some NF-B–regulated genes are induced by 
type I infection, but a much greater number are induced by 
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infection (Fig. 9 A; Gazzinelli et al., 1994; Saeij et al., 2007). 
In fact, the single amino acid difference in ROP16 that causes 
it to be less active in type II strains (Yamamoto et al., 2009) 
may have been selected for in type II strains specifically to 
increase NF-B activation by GRA15II. However, GRA15 
and ROP16 are expected to have additive or synergistic effects 
on the expression of other genes, such as the SOCS genes 
(Fig. S9 A). In any case, the modulation of host cell gene ex-
pression will depend upon the exact allelic combination of a 
variety of factors that T. gondii possesses, including GRA15 
and ROP16.
Early in infection (days 1–5), GRA15 affected both cyto-
kine production and parasite growth in vivo. When a host is 
first infected by live parasites, type II strains expressing GRA15 
activate NF-B in host cells and induce IL-12 secretion, 
whereas infection with type II GRA15KO parasites or type 
I/III strains does not cause this early activation. IL-12 stimu-
lates NK cells and T cells to secrete IFN-, and the observed 
effect of GRA15 on IFN- levels was likely via an effect on 
IL-12. Although levels of IL-12 in the i.p. cavity were not sig-
nificantly different between mice infected with a type II or 
type II GRA15KO strain, the levels were consistently lower 
in type II GRA15KO–infected mice, and this difference may 
have been enough to lead to a significant difference in IFN- 
levels (Fig. 9 D). IFN- is the main mediator of host resis-
tance to T. gondii, and differences in IFN- levels probably 
also explain the growth difference that we observed in vivo 
between a type II and type II GRA15KO strain at a slightly 
later time point 5 d after infection (Fig. 9 C). However, as the 
infection progresses and parasites lyse out of host cells, patho-
gen-associated molecular pattern proteins within the PV, such 
as profilin and cyclophilin, are released, and NF-B will be 
activated via TLR signaling and CCR5 signaling by all strains. 
At this stage, IL-12 production, IFN- production, and para-
site growth are then independent of the GRA15 locus, which 
might explain why a type II strain does not differ in overall 
virulence from a type II GRA15KO strain (Fig. 9 B). The lo-
cation of GRA15 on chromosome X does indicate that it 
could represent a previously identified chromosome X viru-
lence locus (Saeij et al., 2006).
Plaque assays showed that GRA15 also affects parasite 
growth in vitro (Fig. S8 A). However, this in vitro effect oc-
curred specifically in human cells and not in mouse cells. The 
cause of this difference is currently unknown, but one possi-
bility is that genes affecting amino acid levels, lipid levels, or 
levels of other nutrients are partially NF-B regulated in 
human cells but not in mouse cells.
GRA15II may also have other effects in vivo that remain 
untested. As an intracellular pathogen, T. gondii must use host 
cells to traffic through the body of the host animal. NF-B 
activation by GRA15II increases expression of many chemo-
kines and adhesion molecules (our microarray data), and strain 
differences in NF-B activation may therefore lead to differ-
ences in the ability to induce migration of host cells, as previ-
ously reported (Lambert et al., 2006, 2009). Infection of hosts 
with other pathogens is also highly relevant to disease outcome, 
between the type II and type I/III copies of GRA15, includ-
ing an insertion/deletion and several single amino acid changes, 
or the expression level of GRA15 may be responsible for this 
polymorphic phenotype.
Although the GRA15 protein is secreted into the host 
cell upon parasite invasion, cells infected with type I GRA15II 
parasites did not have substantial p65 in their nuclei until 4 h 
after infection (Fig. S4), and in our experiments NF-B acti-
vation was usually assayed 18–25 h after infection. These slow 
kinetics are not unprecedented; Rac GTPase has been shown 
to initiate NF-B nuclear translocation with a time course 
similar to that of GRA15 (Boyer et al., 2004). Additionally, 
the amount of GRA15 interacting with host cell proteins 
likely increases after PV formation as dense granule proteins 
are made and continuously secreted from intracellular para-
sites, and higher levels of GRA15 may be necessary to initiate 
NF-B activation.
The precise mechanism by which GRA15 activates NF-
B has yet to be discovered. Our data suggests that GRA15 
initiates canonical NF-B activation, which preferentially in-
duces the p65/p50 heterodimer (Hayden and Ghosh, 2004). 
A simple hypothesis is that GRA15 acts as a TLR ligand to 
activate the canonical NF-B pathway; however, the activa-
tion of p65 translocation by GRA15 is not dependent on ei-
ther MyD88 or TRIF, two proteins which are essential for 
TLR signaling. We did find that the activity of GRA15 is de-
pendent on both IKK- and TRAF6, suggesting that GRA15 
acts either upstream of or in a complex with these proteins. 
A type I GRA15II strain activated more nuclear p65 translo-
cation in WT MEFs than in IKK-/ or TRAF6/ MEFs, 
although in IKK-/ cells this difference was not significant 
(P = 0.12). This is probably because IKK- also has phos-
phorylating activity. Our microarray data further defines the 
placement of GRA15 in the NF-B signaling pathway. 
GRA15 is able to constitutively activate NF-B, but this acti-
vation leads to the expression of negative feedback regulators, 
such as the deubiquitinating enzymes A20 (TNFAIP3) and 
CYLD, which normally act to quickly down-regulate NF-B 
signaling. Because TRAF6 and the IKK complex are both 
targets of these deubiquitinating enzymes, it is likely that 
GRA15 acts in concert with these proteins rather than up-
stream (Sun, 2008). We are currently looking for direct bind-
ing partners of GRA15 by coimmunoprecipitation.
We found that a type I copy of ROP16 can inhibit 
NF-B activation in a type II strain (Fig. S9 B). Why this 
inhibition occurs in a type II strain but not a type I strain is 
unknown, but the genetic backgrounds of type I and type II 
strains are very different and other polymorphic factors likely 
exist that affect STAT and/or NF-B signaling pathways. 
How ROP16 inhibits NF-B activation is also unclear, but it 
is likely to be through its activation of STAT6 and/or STAT3 
(Ohmori and Hamilton, 2000; Nelson et al., 2003; Butcher 
et al., 2005; Hoentjen et al., 2005). This inhibition has signifi-
cant consequences, for example, GRA15 and ROP16 have 
opposing effects on the expression levels of many genes, in-
cluding IL-12, a particularly important cytokine in T. gondii 
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(Kirkegaard & Perry Laboratories). Purified LPS (EMD), recombinant mouse 
TNF (AbD Serotec), and recombinant human TNF (Invitrogen) were used 
to stimulate cells. MG-132 (EMD) was used in proteasomal inhibition.
IF. Parasites were allowed to invade cells on coverslips and incubated for dif-
ferent time points. The cells were then fixed with 3% (vol/vol) formaldehyde 
in PBS for 20 min at room temperature, permeabilized with 100% ethanol 
and/or 0.2% (vol/vol) Triton X-100, and blocked in PBS with 3% (wt/vol) 
BSA and 5% (vol/vol) goat serum. Coverslips were incubated with primary 
antibody for 1 h at room temperature or overnight at 4°C, and fluorescent 
secondary antibodies and Hoechst dye were used for antigen and DNA visu-
alization, respectively. Coverslips were mounted on a glass slide with Vecta-
shield (Vector Laboratories), and photographs were taken using NIS-Elements 
software (Nikon) and a digital camera (CoolSNAP EZ; Roper Industries) 
connected to an inverted fluorescence microscope (model eclipse Ti-S; Nikon). 
Quantification of nuclear signal was performed by randomly selecting at least 
10 infected cells per T. gondii strain and measuring the mean signal intensity 
per nucleus using the NIS-Elements software and Hoechst dye to define nu-
clei. For evacuole staining, this standard IF protocol was modified slightly. 
Parasites were added to HFFs on coverslips, spun down to bring them into 
contact with host cells, and allowed to attach to and invade host cells for 5 min at 
37°C. Unattached parasites were washed off with PBS, and cells were fixed 
3% (vol/vol) formaldehyde in PBS for 20 min at room temperature, blocked 
in PBS with 5% (vol/vol) fetal bovine serum and 5% (vol/vol) normal goat 
serum for 1–2 h at room temperature, and permeabilized by incubation in 
PBS with 0.2% (wt/vol) saponin at 37°C for 20 min. For proteasomal inhibition 
HFF monolayers were pretreated with 20 ng/ml of MG-132 for 1 h at 37°C. 
Cells were infected with parasites and spun down. 4 h after MG-132 addi-
tion, cells were washed with PBS and fresh media containing no inhibitor 
was added. The monolayer was incubated for one additional hour before fixa-
tion. To synchronize infection during time course assays, HFF monolayers 
were incubated on ice with cold media for 10 min before infection. For infec-
tion, supernatant from fully lysed parasite flasks was pelleted and washed three 
times with PBS and resuspended in cold media. After infection, monolayers were 
incubated on ice for 30 min, and then unattached parasites were washed off 
with cold PBS. Fresh prewarmed media was added and cells were incubated 
at 37°C to allow invasion and infection for the determined length of time.
Generation of transgenic parasites. The GRA15 coding region and pu-
tative promoter (1,940 bp upstream of the start codon) was amplified from 
type II T. gondii genomic DNA by PCR (forward, 5-CCCAAGCTT-
GACTGCCACGTGTAGTATCC-3; reverse, 5-TTACGCGTAGTCC-
GGGACGTCGTACGGGTATGGAGTTACCGCTGATTGTGT-3). 
Sequence coding for an HA tag was included in the reverse primer (denoted 
with italics) to C-terminally tag the protein. GRA15IIHA was then inserted 
into pCR8/GW (Invitrogen) by TOPO-TA cloning. Gateway cassette A was 
ligated into pTKO (gift from G. Zeiner, Stanford University School of Medi-
cine, Stanford, California) at the EcoRV site, creating a Gateway destination 
vector (Invitrogen), pTKO-att (Fig. S10), and GRA15IIHA was cloned into 
pTKO-att by LR recombination (Invitrogen). The pTKO-att-GRA15IIHA 
vector was then linearized by digestion with XhoI (NEB). XhoI cuts off 244 
bp of the putative promoter, leaving 1,696 bp intact upstream of the start 
codon. Linearized vector was transfected into RHHXGPRT and CEP 
HXGPRT C22 parasites by electroporation. Electroporation was done in a 
2-mm cuvette (Bio-Rad Laboratories) with 2 mM ATP (MP Biomedicals) 
and 5 mM GSH (EMD) in a Gene Pulser Xcell (Bio-Rad Laboratories), with 
the following settings: 25 FD, 1.25 kV,  Ω. Stable integrants were selected 
in media with 50 µg/ml mycophenolic acid (Axxora) and 50 µg/ml xanthine 
(Alfa Aesar) and cloned by limiting dilution. Expression of GRA15II was 
confirmed by IF for HA staining. Parasite strains already containing the 
HXGPRT gene (RH GRA15KO and Pru A7 GRA15KO) were cotrans-
fected with 35 µg pTKO-att-GRA15II and 1 µg pTUB5-BLE (Soldati et al., 
1995), containing the ble selectable marker. Stable integrants were selected 
extracellularly with 50 µg/ml Phleomycin (InvivoGen), and HA staining was 
confirmed by IF.
and the activation of NF-B by T. gondii might increase tran-
scription of HIV retroviral sequences with NF-B binding 
sites in their promoters (Gazzinelli et al., 1996). Lastly, NF-B 
activation leads to a proinflammatory Th1-type immune re-
sponse that may promote inflammatory disease manifestations 
such as encephalitis and colitis, both of which have been ob-
served mainly after type II strain infections (Hunter and 
Remington, 1994; Liesenfeld, 1999).
MATERIALS AND METHODS
Parasites and cells. Parasites were maintained in vitro by serial passage on 
monolayers of HFFs at 37°C in 5% CO2. RH or GT1 were used as represen-
tative type I strains, ME49 or Pru as representative type II strains, and CEP or 
VEG as representative type III strains. A Pru strain engineered to express fire-
fly luciferase and GFP (Pru HXGPRT A7; Kim et al., 2007), and CEP and 
RH strains engineered to express click beetle luciferase and GFP (CEP 
HXGPRT- C22 and RH 1–1; Boyle et al., 2007), have been described previ-
ously. Pru and RH strains expressing HXGPRT and generated from unsuc-
cessful knockout transfections were used in assays comparing parasite growth. 
F1 progeny from type II × type III crosses were described previously (Sibley 
et al., 1992; Khan et al., 2005). A Pru strain expressing a type I copy of 
ROP16 was also described previously (Saeij et al., 2007). HFFs were grown 
in DME (Invitrogen) supplemented with 10% heat inactivated FBS (PAA), 
2 mM l-glutamine, 50 µg/ml each of penicillin and streptomycin, and 
20 µg/ml gentamycin. BMMs were obtained from female BALB/c, C57BL/6, 
or MyD88/TRIF double knockout (a gift from H. Ploegh, Whitehead Insti-
tute for Biomedical Research and Massachussetts Institute of Technology, 
Cambridge, MA) mice. BM was isolated by flushing hind tibias and femurs 
using a 27-gauge needle and/or by crushing the bones using a mortar and 
pestle, followed by passage over a cell strainer. Cells were suspended in DME 
supplemented with 20% L929 cell-conditioned medium, 10% heat-inactivated 
FBS, 2 mM l-glutamine, 1 mM sodium pyruvate, 1× MEM nonessential 
amino acids, and 50 µg/ml each of penicillin and streptomycin. 3–6 × 106 
cells were plated in 10-cm nontissue culture–treated dishes (VWR) and in-
cubated at 37°C, with 5% CO2 in humidified air. After 6–7 d, cells were 
washed with PBS to remove nonadherent cells, harvested by dislodging with 
a cell scraper in PBS, and replated for the assay. 293 stable cell lines with four 
copies of the NF-B consensus transcriptional response element driving the 
expression of GFP or GFP and luciferase (System Biosciences) were grown 
in DME supplemented with 10% heat-inactivated FBS, 2 mM l-glutamine, 
1 mM sodium pyruvate, 1× MEM nonessential amino acids, 10 mM HEPES, 
50 µg/ml each of penicillin and streptomycin, and 20 µg/ml gentamycin. 293 
cells were passed every 2–4 d using 0.05% trypsin-EDTA. WT MEFs were 
gifts from M. Karin (University of California, San Diego, School of Medicine, 
La Jolla, CA) and A. Sinai (University of Kentucky College of Medicine, 
Lexington, KY), IKK-/ MEFs were a gift from M. Karin (Li et al., 1999), 
NF-Bp65/ MEFs were a gift from A. Sinai, and TRAF6/ MEFs were 
provided by K. Fitzgerald (University of Massachussetts Medical School, 
Worcester, MA). MEFs were grown in DME supplemented with 10% non-
heat inactivated FBS (PAA), 2 mM l-glutamine, 1 mM sodium pyruvate, 
1× MEM nonessential amino acids, 10 mM Hepes, and 50 µg/ml each of 
penicillin and streptomycin. MEFs were passed using 0.05% trypsin-EDTA. 
All parasite strains and cell lines were routinely checked for Mycoplasma 
contamination and it was never detected.
Reagents. Antibodies against HA (3F10; Roche), mouse NF-B p65 
(sc-8008), human NF-B p65 (sc-109), NF-B p50 (sc-8414), NF-B p52 
(sc-7386), NF-B RelB (sc-28689), NF-B c-Rel (sc-71), T. gondii surface 
antigen (SAG)-1 (DG52; Burg et al., 1988), T. gondii dense granule protein 
GRA7 (Dunn et al., 2008), T. gondii rhoptry protein ROP1 (Tg49; Ossorio 
et al., 1992), phospho-IB (sc-8404), total IB (sc-847), and GAPDH (sc-
32233) were used in the IF assay or in Western blotting. IF secondary anti-
bodies were coupled with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen). 
Secondary antibodies used in Western blotting were conjugated to peroxidase 
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by TNF stimulation, and all MEF samples. 18–24 h after infection or 6 h after 
stimulation, total RNA was isolated using TRIzol reagent (Invitrogen) ac-
cording to the manufacturer’s protocol and cleaned up using RNeasy Mini 
or MinElute kit (QIAGEN). RNA was labeled and hybridized to a human 
or mouse Affymetrix array (Human U133A 2.0 or Mouse 430A 2.0) accord-
ing to the manufacturer’s protocol. Probe intensities were measured with the 
Affymetrix GeneChip Scanner 3000 7G and were processed into image 
analysis (.CEL) files with either GeneChip Operating Software or Expression 
Console Software (Affymetrix). Intensity values were normalized using the 
MAS5 algorithm such that the median intensity on the array was 500 using 
Expression Console software. The MAS5 algorithm gives a signal intensity 
value for every probe as well as a present, marginal, or absent call, based on 
mismatch probes. For all probes called present, signal intensity values <50 
were increased to a minimum value of 50. For all probes called marginal or 
absent, the signal intensity value was set to 50. Expression data were clustered 
using MultiExperiment Viewer (Saeed et al., 2003, 2006). Microarray data has 
been uploaded to GEO Datasets under accession number GSE 25476.
Gene set enrichment analysis (GSEA) was used to find candidate tran-
scription factors and canonical pathways that are modulated differently 
between T. gondii infections (Mootha et al., 2003; Subramanian et al., 2005). 
This program uses a priori–defined sets of genes and determines whether the 
members of these sets of genes are randomly distributed throughout a ranked 
list or primarily found at the top or bottom. As GSEA is generally used to 
generate hypotheses, gene sets enriched with a false discovery rate <0.25 
were considered significant. Both transcription factor and canonical pathway 
gene sets from the Molecular Signatures Database were evaluated for enrich-
ment (c2.cp.v2.5.symbols, c3.tft.v2.5.symbols.gmt; Subramanian et al., 2005). 
The gsea2 java release was run using all default settings. For analyses on RH 
GRA15KO, TNF, and RH HXGPRT + TNF, and all MEF infections, for 
which we only did one array, MOI-matched arrays and the GSEA preranked 
function were used.
Distant regulatory elements of coregulated genes (DiRE; Gotea and 
Ovcharenko, 2008) and ingenuity pathway analysis (IPA) were also used. For 
every gene in a list, DiRE detects regulatory elements throughout the entire 
gene locus and looks for enrichment of TFBSs. IPA takes a list of genes and 
overlays them onto a global molecular network developed from information 
contained in the Ingenuity Pathways Knowledge Base. Networks of these 
genes are then algorithmically generated based on their connectivity. A network 
is a graphical representation of the molecular relationships between genes/
gene products. Genes or gene products are represented as nodes, and the bio-
logical relationship between two nodes is represented as an edge. All edges are 
supported by at least one reference from the literature, from a textbook, or 
from canonical information stored in the Ingenuity Pathways Knowledge 
Base. The two networks with the highest score are indicated.
5 and 3 RACE. Total RNA was isolated from HFFs infected with Pru para-
sites using TRIzol reagent (Invitrogen) and cleaned up using the RNeasy Mini 
kit (QIAGEN). RACE-ready cDNA was synthesized using a GeneRacer kit 
with SuperScript III RT (Invitrogen). Nested PCR was done on the RACE-
ready cDNA to determine both 5 and 3 transcript ends using gene-specific 
primers (5 GRA15reverse, 5-AGTCCTCCCCGTTTTCGGTCTGTT-3; 
5 GRA15 nested reverse, 5-GACTCTGAACGGGGACGGGTAGTC-3; 
3 GRA15 forward, 5-CTGTCCACTCAATAGACCCCGTTGT-3; and 
3 GRA15 nested forward, 5-AAGATGCCGTGCAAAGCCAACTTC-3), 
provided GeneRacer 5 and 3 primers, and Phusion enzyme (Finnzymes). 
PCR products were cloned into the pCR4Blunt-TOPO vector (Invitrogen) 
and sequenced. Sequences were analyzed with Sequencher software 
(Gene Codes).
Characterization of GRA15 sequence. The coding sequence for GRA15 
from types I (GT1), II (ME49), and III (VEG) was predicted from ToxoDB 
genomic sequence using ORF Finder (National Center for Biotechnology 
Information). GRA15 genomic DNA from additional strains (RH, Pru, 
CEP) was amplified by PCR and sequenced (forward, 5-TCCGACT-
CAGTGCGGGAAA-3; and reverse, 5-ATCCAGGTCCCCAAAGG-3). 
The ROP2 and GRA6 coding regions and putative promoters (at 
least 1,500 bp upstream of the start codon) were amplified from type II 
T. gondii genomic DNA by PCR (ROP2 forward, 5-CACCGAGGTTG-
GAACTGTG-3; ROP2 reverse, 5-CTTACGCGTAGTCCGGGAC- 
GTCGTACGGGTAGATTGCCGTAACCGCCT-3; GRA6 forward, 
5-CCCAAGCTTGAAGGACTGCGTTGAGTGTTTT-3; and GRA6 
reverse, 5-GGAATTCTTACGCGTAGTCCGGGACGTCGTACGGG - 
TAAAAATCAAACTCATTCACACTTC-3). Sequence coding for an HA 
tag was included in the reverse primers (denoted with italics) to C-terminally 
tag the proteins. ROP2IIHA was then inserted into pENTR/D (Invitrogen) 
and GRA6IIHA was inserted into pCR8/GW (Invitrogen) by TOPO clon-
ing, and then cloned into pTKO-att by LR recombination (Invitrogen). The 
vectors were then linearized by digestion with NotI (NEB) and transfected 
into parasites by electroporation. Electroporation and selection was done as 
in the previous paragraph, and HA staining was confirmed by IF.
Generation of GRA15 knockout. A targeting construct (Fig. S5 A) was 
engineered using a modified pTKO-att vector, pTKO2, and Multisite Gate-
way Pro 3-Fragment Recombination (Invitrogen). The hypoxanthine-xan-
thine-guanine ribosyl transferase (HXGPRT) selectable marker was removed 
from pTKO-att by Cre recombinase (NEB) to form pTKO2 (Fig. S10). 
5 and 3 flanking regions of GRA15 were cloned from type I and type 
II genomic DNA. Primers contained att recombination sites (denoted in 
primer sequence with italics) and amplified 2,083 bp, 100 bp upstream of the 
GRA15 start codon and 2,071 bp, 34 bp downstream of the GRA15 stop 
codon (5 forward, 5-GGGGACAAGTTTGTACAAAAAAGCAGGCTT- 
AAGGGTCTGAACGTGTGCA-3; 5 reverse, 5-GGGGACAACTTTG - 
TATAGAAAAGTTGGGTGACCCGGCTTAAGTTGGTG-3; 3 forward, 
5-GGGGACAACTTTGTATAATAAAGTTGCATGACCAAAAACC-
GATAA-3; and 3 reverse, 5-GGGGACCACTTTGTACAAGAAAGCT- 
GGGTACAAGTCGGCACATGCTTAGA-3). These flanking regions 
were then cloned around the HXGPRT selectable marker flanked by 5 
and 3 UTRs from DHFR, amplified from pTKO with primers containing 
att recombination sites (denoted in primer sequence with italics; DHFR::
HPT forward, 5-GGGGACAACTTTTCTATACAAAGTTGCTCA-
GCACGAAACCTTGCAT-3; and DHFR::HPT reverse, 5-GGGGA- 
CAACTTTATTATACAAAGTTGTGTGTCACTGTAGCCTGCC-3). 
Before transfection, the knockout vector was linearized with the restriction 
enzyme NotI (NEB). RHHXGPRT, PruHXGPRT, and PruHXGPRT 
A7 parasites were transfected with the knockout construct by electropora-
tion, as described in the previous section. Stable integrants were selected as 
in the previous section and cloned by limiting dilution. PCR with a for-
ward primer upstream of the 5 flanking region (P1, 5-CATGGATGCTA-
ATCGGCTTT-3) and a reverse primer within the HXGPRT cassette (P2, 
5-GATCCAGACGTCTTCAATGC-3; and P3, 5-GGGGACAACTT-
TATTATACAAAGTTGTGTGTCACTGTAGCCTGCC-3) confirmed a 
disruption in the GRA15 locus. Additionally, PCR was done to confirm the 
inability to amplify GRA15 (P4, 5-GATGATGGATCCATAATTCGGT-
GGCTTGGG-3; and P5, 5-GGGGACCACTTTGTACAAGAAAGCT-
GGGTATCGGCACATGCTTAGAAG-3; Fig. S5 B).
Microarray. For human arrays, HFFs were grown in a T25 to confluency. 
Parasite strains were syringe lysed and washed once with PBS. HFFs were in-
fected with Pru HXGPRT A7, Pru HXGPRT, Pru A7 GRA15KO, Pru 
GRA15KO, RH 1–1, RH HXGPRT, RH GRA15II (a transgenic RH 
strain expressing a type II copy of GRA15), RH GRA15KO, CEP HXG-
PRT C22, or CEP C22 GRA15II (a transgenic CEP strain expressing a type 
II copy of GRA15) at varying MOIs. For mouse arrays, WT or p65/ MEFs 
were grown in a 12-well plate to confluency. Parasite strains were syringe 
lysed and washed twice with PBS. MEFs were infected with Pru HXGPRT 
A7, Pru A7 GRA15KO, RH 1–1, or RH GRA15II at varying MOIs.
Plaque assays were done to assess viability of parasites and infections with 
similar MOIs were chosen. Some samples were also stimulated with TNF. At 
least two biological replicates were done for every sample, except RH 
GRA15KO infection, TNF stimulation, RH HXGPRT preinfection followed 
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Committee on Animal Care approved all protocols. All mice were maintained 
in specific pathogen-free conditions, in accordance with institutional and 
federal regulations.
i.p. wash and in vivo cytokine ELISA. 1 or 2 d after i.p. infection, mice 
were sacrificed and the i.p. cavity was washed with 5 ml PBS. The i.p. wash 
was spun at 450 g for 5 min to pellet cells. Supernatant was collected and 
stored at 80°C if necessary. IFN-, IL-12p40, and IL-12p70 levels were de-
termined using commercially available ELISA kits (ELISA Ready-SET-Go!; 
eBioscience) according to the manufacturer’s instructions.
Plaque assay. For all assays comparing the effect of T. gondii on the host cell, 
cells were infected with different MOIs and a plaque assay was done to de-
termine the viability of each strain. The infections with the closest MOIs 
were then used. For the plaque assay, 100 parasites per well were added to 
confluent HFFs in a 24-well plate and were incubated for 5–7 d at 37°C. The 
number of plaques was counted using a microscope. Plaque assays were also 
performed to assess the viability of parasites used to infect mice. To assay in 
vitro parasite growth, plaque size was measured using NIS-Elements software 
(Nikon) and a digital camera (CoolSNAP EZ; Roper Scientific) connected 
to an inverted fluorescence microscope (eclipse Ti-S; Nikon).
Online supplemental material. Fig. S1 shows that a type II locus on 
chromosome X strain-specifically induces expression of NF-B–regulated 
genes. Fig. S2 shows mapping the strain-specific activation of NF-B. 
Fig. S3 shows that type III strains complemented with GRA6 or ROP2 
do not activate NF-B. Fig. S4 shows time course of NF-B activation by 
GRA15II. Fig. S5 shows generation and confirmation of GRA15KO. Fig. S6 
shows GRA15 activation of NF-B family subunits. Fig. S7 shows GRA15 
amino acid alignment. Fig. S8 shows that GRA15 affects in vitro parasite 
growth and inhibits in vivo parasite growth in a type I background. Fig. S9 
shows that ROP16 can affect the expression of GRA15-regulated genes. 
Fig. S10 shows pTKO, pTKO-att, and pTKO2 vectors. Supplemental data 1 
shows GSEA gene sets. Supplemental data 2 shows complete heat map gene 
lists. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20100717/DC1.
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